<DOC>
	<DOCNO>NCT00010127</DOCNO>
	<brief_summary>RATIONALE : Vaccines make person 's cancer cell may make body build immune response kill prostate tumor cell . PURPOSE : Phase I trial study effectiveness vaccine therapy treat patient metastatic prostate cancer .</brief_summary>
	<brief_title>Vaccine Therapy Treating Patients With Metastatic Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine safety feasibility autologous dendritic cell transfected autologous total tumor RNA patient metastatic prostate cancer . - Determine presence , frequency , activation status tumor specific prostate specific antigen ( PSA ) specific cellular immune response patient treat regimen . - Determine delayed-type hypersensitivity reaction PSA protein recall antigen patient treat regimen . - Determine clinical response base clinical biochemical ( PSA ) response criterion patient treat regimen . - Determine platform immunological treatment use dendritic-cell base tumor vaccine patient . OUTLINE : This dose escalation study . Tumor tissue peripheral blood stem cell collect patient cultured vitro sargramostim ( GM-CSF ) interleukin-4 7 day produce dendritic cell ( DC ) . Patients receive autologous DC transfected autologous prostate carcinoma RNA intradermally weekly week 0-3 total 4 dos . Cohorts 3-6 patient receive escalate dos DC maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Patients follow week 6 , 8 , 10 , 12 ; every 3 month 9 month ; annually 2 year . PROJECTED ACCRUAL : A total 18 patient accrue study within 20 month .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic adenocarcinoma prostate Stage D13 Regional lymph node , bone , visceral , soft tissue metastases No transitional cell small cell carcinoma Testosterone le 50 mg/L prior treatment luteinizing hormone release hormone ( LHRH ) analogues estrogens Evidence androgen refractory disease surgical castration discontinuation LHRH analogue therapy No previously irradiate new CNS metastases PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70100 % Life expectancy : More 6 month Hematopoietic : WBC least 3,000/mm^3 Hemoglobin least 9 g/dL Platelet count least 100,000/mm^3 Hepatic : Bilirubin le 2.0 mg/dL PT least 11.3 second great 13.3 second PTT least 20.1 second great 32.9 second No hepatic disease No viral hepatitis Renal : Creatinine le 2.5 mg/dL Cardiovascular : No New York Heart Association class III IV heart disease Pulmonary : No asthma No chronic obstructive pulmonary disease No severe lung disease Other : No medical illness psychological impediment would preclude study No concurrent malignancy except nonmelanoma skin cancer control superficial bladder cancer No active acute chronic infection include symptomatic urinary tract infection No autoimmune disease ( e.g. , inflammatory bowel disease , systemic lupus erythematosus , rheumatoid arthritis , ankylose spondylitis , scleroderma , multiple sclerosis ) HIV negative Adequate peripheral vein access PRIOR CONCURRENT THERAPY : Biologic therapy : Prior biologic therapy allow No concurrent immunotherapy Chemotherapy : Prior chemotherapy allow No concurrent chemotherapy Endocrine therapy : See Disease Characteristics At least 4 week since prior nonsteroidal hormonal therapy increase PSA receive nonsteroidal hormonal therapy At least 6 week since prior steroid Concurrent LHRH analogues gonadal androgen suppression allow No concurrent steroid therapy No concurrent corticosteroid Radiotherapy : See Disease Characteristics Prior palliative radiotherapy bone metastases allow Prior prostatic radiotherapy allow At least 4 week since prior radiotherapy At least 12 week since prior strontium chloride Sr 89 No concurrent radiotherapy Surgery : See Disease Characteristics Other : Recovered prior therapy No concurrent immunosuppressive agent ( e.g. , azathioprine cyclosporine )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage IV prostate cancer</keyword>
</DOC>